VINCERX PHARMA INC (VINC) Stock Income Statement
NASDAQ:VINC - Nasdaq - US92731L3042 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-6-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 31.46M | 42.61M | 68.72M | 62.66M | 173.00K | |||
| Research and Development | 15.49M | 28.97M | 49.84M | 40.08M | 7.12M | |||
| Selling, General, and Administrative Expenses | 15.98M | 13.64M | 18.89M | 22.57M | 3.60M | |||
| Operating Income | -31.46M | -42.61M | -68.72M | -62.66M | -173.00K | |||
| Interest Income/Expense | 472.00K | 1.25M | 664.00K | 0.00 | 54.30K | |||
| Other Income/Expense | 822.00K | 1.20M | 7.54M | 23.35M | -5.14M | |||
| Non Recurring Items | N/A | 0.00 | -2.47M | N/A | N/A | |||
| Income Before Taxes | -30.07M | -40.16M | -62.98M | -39.31M | -118.70K | |||
| Income Tax | N/A | N/A | N/A | N/A | 800.00 | |||
| Net Income | -30.07M | -40.16M | -62.98M | -39.31M | -119.50K | |||
| EBITDA | -31.41M | -42.56M | -68.67M | -62.63M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -15.85 | -37.71 | -59.90 | -45.77 | -1.41 | |||
| Non GAAP EPS | -20.20 | -1.89 | -3.12 | -2.28 | N/A | |||
| Statistics | ||||||||
All data in USD